

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2026

Enovix Corporation

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

001-39753

(Commission
File Number)

85-3174357

(IRS Employer
Identification No.)

3501 W Warren Avenue
Fremont, California

(Address of Principal Executive Offices)

94538

(Zip Code)

Registrant's Telephone Number, Including Area Code: (510) 695-2350

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	ENVX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2026, Enovix Corporation (the “Company”) issued a press release announcing the release of its financial results for the second fiscal quarter 2026. A copy of the press release is attached as Exhibit 99.1 to this report.

The information in this current report on Form 8-K and the exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Q2 2026 Financial Results Press Release dated August 12, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 12, 2026

Enovix Corporation

By: /s/ Arthi Chakravarthy

Arthi Chakravarthy
Chief Legal Officer



Enovix Reports Second Quarter 2026 Results

Second Quarter Revenue of \$9.0 Million, Up 21% Year-over-Year, at High End of Guidance; First Half 2026 Revenue of \$16.6 Million, Up 32% Year-over-Year

Lead Smartphone Customer Confirms Passing More than 1,000 Cycles under the 0.2C Discharge Cycle Test¹; Final Accelerated Cycle-Life Test for Smartphone Qualification Underway, with Completion Expected in 2026

FREMONT, Calif., August 12, 2026 -- Enovix Corporation (Nasdaq: ENVX) ("Enovix"), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, today reported financial results for the second quarter of 2026.

Second Quarter 2026 Highlights

- Revenue of \$9.0 million, up 21% year-over-year and 19% sequentially, at the high end of guidance — fifth consecutive quarter of year-over-year revenue growth; year-to-date revenue of \$16.6 million, up 32% year-over-year.
- Seventh consecutive quarter of positive gross profit, with GAAP gross margin of 14.4% and non-GAAP gross margin of 19.9%, down 11.6 and 10.9 percentage points, year-over-year, respectively, on a shift in battery product mix; year-to-date GAAP gross margin of 17.2% and non-GAAP gross margin of 22.8%, down 0.3 and up 1.5 percentage points year-over-year, respectively.
- GAAP net loss per share of \$0.20 and non-GAAP net loss per share of \$0.13, compared to \$0.22 and \$0.13, respectively, in the prior-year quarter.
- Lead smartphone customer confirms Enovix batteries passing more than 1,000 cycles under the 0.2C discharge cycle test¹. Final accelerated cycle-life test for smartphone qualification is underway — built around a hybrid protocol defined in close collaboration with the customer and designed for silicon-anode cells.
- Smart eyewear ramp underway: shipped approximately 2,100 AI-1™ batteries, completed key international safety certifications, and recognized initial smart eyewear revenue; third quarter shipments expected to increase approximately 9x from the second quarter to approximately 19,000 packs against the 50,000-pack order.
- Drone, defense, and industrial pipeline grew to \$183 million, up approximately 41% from \$130 million at the end of the first quarter, driven substantially by drone opportunities, which exceeded \$100 million during the second quarter.
- Third quarter 2026 outlook: revenue of \$9.0 to \$10.0 million, up approximately 13% to 25% year-over-year; full guidance detailed in the Financial Outlook section.

¹ Standard accelerated cycle-life testing condition based on a combination of 0.2C (2%) and 0.7C (98%) cycles used by customers as proxy for 0.2C cycle life. Blended average time per cycle ≈ 2.4 hours.

- Ended the quarter with approximately \$552.1 million in cash, cash equivalents, and marketable securities, including restricted cash.

“The second quarter showed momentum across all three of our target markets: our lead customer confirmed passing a defining smartphone qualification milestone. We have one final accelerated cycle-life test on the path to smartphone qualification, which we expect to complete this year. We also converted our smart eyewear ramp into initial revenue and substantially expanded our drone and defense pipeline,” said Dr. Raj Talluri, President and CEO of Enovix. “With revenue up 21% year-over-year at the high end of guidance and our fifth consecutive quarter of year-over-year growth, Enovix is executing the transition from technology validation to commercial scale.”

Commercialization Progress: Smartphones

Customer testing is now underway with the final accelerated cycle-life test, aligned through an iterative customer engagement process. This hybrid approach, which replaced the traditional 0.7C test used for legacy graphite batteries, consists of multiple test protocols across a range of charge and discharge conditions, with testing durations differing by variant mix. The lead customer is currently evaluating Enovix’s cells, including an enhanced design, across these multiple variants. The Company anticipates completing this final accelerated test in the fourth quarter of 2026, with targeted system-level field testing to follow.

Enovix’s second smartphone OEM customer continues to progress toward alignment on a qualification framework, following a path parallel to that of the lead customer. The Company expects to begin sample deliveries in the fourth quarter of 2026.

Commercialization Progress: Smart Eyewear

“Our smart eyewear business recently marked several important milestones. We completed the international safety certifications required for commercial deployment, advanced our manufacturing ramp, and generated initial product revenue this quarter. Our next-generation AI-2™ batteries are now in customers’ hands, and we expect them to be well received,” said Dr. Talluri. “We believe these milestones, achieved on a 100% silicon-anode battery in commercial production, further validate that our proprietary cell architecture can be manufactured, certified, and deployed at commercial scale.”

Enovix’s smart eyewear ramp is well underway. Recently, Enovix completed key international safety certifications for its smart eyewear cells and battery packs, including UN 38.3 transportation testing, UL 2054, and KC 62133-2, and passed the full suite of customer reliability tests covering drop, tumble, thermal cycling, and extended heat soak.

Following the start of commercial production in the first quarter, the Company shipped approximately 2,100 silicon-anode AI-1 batteries during the second quarter to support a leading smart eyewear reference platform and recognized initial smart eyewear product revenue. These shipments are being made under a customer order covering 50,000 battery packs for 2026 delivery. The customer has since issued delivery orders (specifying quantities and timing) under that same 50,000-pack order for approximately 19,000 packs to be delivered in the

third quarter — an approximately 9x increase over second-quarter shipments. The Company expects to fulfill the balance of the 50,000-pack order during the fourth quarter of 2026, with shipment volumes expected to grow in 2027 as downstream deployments are projected to expand.

Commercialization Progress: Drones, Defense, and Industrial

“Our defense and drone business delivered another quarter of strong growth and pipeline expansion,” said Dr. Talluri. “We are investing now to expand capacity so we can convert our growing pipeline into revenue as customer programs reach launch.”

Demand across Enovix’s drone, defense, and industrial markets continued to expand in the second quarter. The Company’s global pipeline for products manufactured in South Korea increased 41% to approximately \$183 million, up from \$130 million at the end of the first quarter, with more than half of the growth driven by drone opportunities. Drone opportunities alone exceeded \$100 million during the second quarter, with a substantial portion at stages where customers are actively evaluating and testing the Company’s cells or designing them into products. This pipeline represents the Company’s estimate of the peak annual production value of identified design opportunities.

Enovix showcased the recently launched MX-1™ at industry conferences across the U.S. and Europe during the quarter, with customer interest in the MX1-B01™ drone cell continuing to grow. In particular, military customers are seeking products that satisfy various governmental requirements, and the Company is well-positioned to meet this demand. The product and transportation certifications necessary to support expanded customer sampling and initial deliveries are progressing well. Subsequent to quarter end, the Company commenced sampling to numerous customers in the third quarter and its drone battery passed UN 38.3 transportation testing, completing a key certification required for commercial shipment. Enovix believes demand for high-performance drone batteries that meet U.S. government sourcing requirements under the National Defense Authorization Act (NDAA) and the Trade Agreements Act (TAA) will materially exceed available supply through the end of the decade. Enovix’s South Korea manufacturing operations, with an established production history supporting defense customers, position the Company to be a scaled supplier able to address this gap, and the previously announced capacity expansion at the facility is underway, with the new capacity expected to come online in mid-2027. The expansion is expected to be capital-efficient, utilizing existing land and buildings the Company already owns and leveraging readily available production equipment.

Technology Progress

In the first quarter of 2026, Enovix produced the first engineering samples of AI-2, a next-generation smart eyewear battery expected to deliver approximately 20% higher volumetric energy density than AI-1. AI-2 leverages the EX-3M™ technology node, which reduces separator and current collector thickness, improves packaging efficiency, and increases cathode voltage. One tier 1 smart eyewear customer commenced sampling during the second quarter, and additional tier 1 customers are expected to receive samples in the third quarter. The same EX-3M innovations are also expected to support a step-function in performance gains for Enovix’s future smartphone batteries.

Enovix is also advancing the energy density of the silicon-blended graphite batteries produced at its South Korea facility. MX-2™, the next generation of the recently launched MX-1 drone cell, remains targeted for 2027, with a goal of reaching a gravimetric energy density of 400 Wh/kg — a significant advancement for this battery chemistry. Gravimetric energy density is especially critical in drone applications, where every gram of battery weight directly impacts flight time, range, payload capacity, and overall operational effectiveness.

Manufacturing Readiness Progress

Enovix continued to improve execution across Fab2 production zones. In smart eyewear battery production, all but one process step outside of Zone 1 delivered yields during the second quarter of 95% or greater, with individual steps as high as 99.6%. Zone 1 dicing — a key throughput driver across our smartphone and smart eyewear production lines — delivered step-level yield of approximately 84% in the second quarter, up from approximately 80% reported last quarter.

To further improve throughput and cost efficiency, the Company has been implementing a hybrid dicing configuration that combines laser and mechanical dicing in Zone 1. This approach allows Enovix to apply the most effective technique at each step and is expected to reduce cell cost while increasing production rates to support early commercial demand as qualification progresses. The transition to mechanical dicing equipment is well underway, with multiple key dicing steps expected to come online at Fab2 around the end of the year.

In parallel, Enovix is streamlining the manufacturing flow by eliminating select process steps, which is expected to further improve manufacturability, throughput, and yield while reducing capital intensity and unit costs. These initiatives reflect the Company's ongoing focus on continuously improving efficiency and scalability across its manufacturing operations.

Leadership

As recently announced, Enovix appointed Michael Vyvoda to serve as its Chief Operating Officer to lead the Company's next phase of global manufacturing execution. Mr. Vyvoda brings decades of operations leadership, including prior experience at Apple, and will oversee manufacturing, supply chain, quality, and customer delivery as Enovix scales production across multiple products, facilities, and end markets. His immediate focus is on scaling production to meet the Company's second-half commitments: ramping smart eyewear output, preparing manufacturing for smartphone field-test builds, and driving the cost, yield and delivery initiatives underway across Enovix's factories.

Subsequent to quarter-end, Enovix also strengthened its commercial organization with a senior sales executive who spent nearly two decades at a leading global manufacturer of lithium-ion batteries for consumer devices, where he most recently headed its largest global sales region and built long-standing relationships across major smartphone OEMs.

Second Quarter and Year-to-Date 2026 Financial Results

(in millions, except percentages)

- Second quarter 2026 revenue of \$9.0 million increased 21% year-over-year and rose 19% sequentially, at the high end of the Company's guidance range and marking the fifth consecutive quarter of year-over-year revenue growth. Year-to-date, revenue of \$16.6 million increased 32% from the first half of 2025. Growth in both periods primarily reflects continued strength in defense through Enovix's South Korea operations, where the Company's global pipeline grew to approximately \$183 million during the period, driven substantially by new drone opportunities. Enovix also achieved commercial availability of its 100% silicon-anode smart eyewear battery during the second quarter and recognized initial smart eyewear product revenue — modest in amount, but an early proof point of contribution from AI-powered wearable devices.
- GAAP gross profit was \$1.3 million and non-GAAP gross profit was \$1.8 million in 2Q26, marking the seventh consecutive quarter of positive gross profit on both a GAAP and non-GAAP basis and continued progression toward economically scalable production. GAAP gross margin was 14.4% and non-GAAP gross margin was 19.9%, down year-over-year primarily due to a shift in the mix of battery products sold through Enovix's South Korea operations. Year-to-date, GAAP gross profit was \$2.9 million and non-GAAP gross profit was \$3.8 million, up from \$2.2 million and \$2.7 million in the first half of 2025, with non-GAAP gross margin improving to 22.8% from 21.3% on higher production volumes and operational execution improvements.
- Net cash used in operating activities improved to \$21.8 million in 2Q26 from \$25.9 million in 2Q25. Free cash flow was an outflow of \$31.4 million in 2Q26, compared to an outflow of \$33.8 million in 2Q25. The modest year-over-year improvement primarily reflects favorable changes in working capital, partially offset by higher capital expenditures supporting manufacturing scale-up. For the first half of 2026, net cash used in operating activities was \$54.9 million and free cash flow was an outflow of \$67.7 million, compared to \$42.8 million and \$57.0 million, respectively, in the first half of 2025. The increase in year-to-date cash use primarily reflects greater working capital usage in the first quarter of 2026 and higher interest expense associated with the semi-annual interest payment of the Company's convertible notes issued in the third quarter of 2025.
- Cash, cash equivalents, and marketable securities, including restricted cash, totaled approximately \$552.1 million at quarter-end, providing liquidity to support qualification completion and commercialization scale-up. Enovix continues to prioritize disciplined capital allocation as it advances manufacturing scale-up and commercialization, while maintaining flexibility to pursue select strategic opportunities. No shares were repurchased during the quarter under the Company's previously authorized share repurchase program. The Company continues evaluating capital deployment alternatives under its existing authorization.

Second Quarter 2026 Financial Summary

(unaudited, in millions, except per share data and percentages)

Note: Amounts may not sum and percentages may not recompute due to rounding.

	GAAP			Non-GAAP		
	Q2 2026	Q2 2025	YoY Δ	Q2 2026	Q2 2025	YoY Δ
Revenue	\$ 9.0	\$ 7.5	\$ 1.5	\$ 9.0	\$ 7.5	\$ 1.5
Gross profit	\$ 1.3	\$ 1.9	\$ (0.6)	\$ 1.8	\$ 2.3	\$ (0.5)
Gross margin	14.4 %	26.0 %	(11.6)pts	19.9 %	30.8 %	(10.9)pts
Operating expenses	\$ 44.6	\$ 45.7	\$ (1.1)	\$ 30.6	\$ 28.8	\$ 1.8
Loss from operations	\$ (43.3)	\$ (43.7)	\$ 0.4	\$ (28.8)	\$ (26.5)	\$ (2.3)
Net cash used in operating activities	\$ (21.8)	\$ (25.9)	\$ 4.1	\$ (21.8)	\$ (25.9)	\$ 4.1
Capital expenditures ⁽¹⁾	\$ (9.6)	\$ (8.0)	\$ (1.6)	\$ (9.6)	\$ (8.0)	\$ (1.6)
Free cash flow	N/A	N/A	N/A	\$ (31.4)	\$ (33.8)	\$ 2.4
Adjusted EBITDA	N/A	N/A	N/A	\$ (18.9)	\$ (20.1)	\$ 1.2
Net loss per share, basic ⁽²⁾	\$ (0.20)	\$ (0.22)	\$ 0.02	\$ (0.13)	\$ (0.13)	\$ —
Weighted average shares, basic ⁽³⁾	218.5	204.8	13.7	218.5	204.8	13.7
Net loss per share, diluted ⁽²⁾	\$ (0.20)	\$ (0.22)	\$ 0.02	\$ (0.13)	\$ (0.13)	\$ —
Weighted average shares, diluted ⁽³⁾	218.5	204.8	13.7	218.5	204.8	13.7

⁽¹⁾ Capital Expenditures reflects cash paid for property, equipment, and manufacturing assets and is a component of our free cash flow calculation. It excludes depreciation, accretion and amortization, and other non-cash investing items. It excludes one-time cash outflows related to business acquisitions. ⁽²⁾ Net loss per share attributable to Enovix. ⁽³⁾ Weighted average shares attributable to Enovix.

2026 Year-to-Date Financial Summary

(unaudited, in millions, except per share data and percentages)

Note: Amounts may not sum and percentages may not recompute due to rounding.

	GAAP			Non-GAAP		
	YTD 2026	YTD 2025	YoY Δ	YTD 2026	YTD 2025	YoY Δ
Revenue	\$ 16.6	\$ 12.6	\$ 4.0	\$ 16.6	\$ 12.6	\$ 4.0
Gross profit	\$ 2.9	\$ 2.2	\$ 0.7	\$ 3.8	\$ 2.7	\$ 1.1
Gross margin	17.2 %	17.5 %	(0.3)pts	22.8 %	21.3 %	1.5pts
Operating expenses	\$ 90.0	\$ 88.5	\$ 1.5	\$ 61.3	\$ 57.1	\$ 4.2
Loss from operations	\$ (87.2)	\$ (86.3)	\$ (0.9)	\$ (57.5)	\$ (54.5)	\$ (3.0)
Net cash used in operating activities	\$ (54.9)	\$ (42.8)	\$ (12.1)	\$ (54.9)	\$ (42.8)	\$ (12.1)
Capital expenditures ⁽¹⁾	\$ (12.8)	\$ (14.2)	\$ 1.4	\$ (12.8)	\$ (14.2)	\$ 1.4
Free cash flow	N/A	N/A	N/A	\$ (67.7)	\$ (57.0)	\$ (10.7)
Adjusted EBITDA	N/A	N/A	N/A	\$ (39.3)	\$ (40.9)	\$ 1.6
Net loss per share, basic ⁽²⁾	\$ (0.37)	\$ (0.33)	\$ (0.04)	\$ (0.27)	\$ (0.26)	\$ (0.01)
Weighted average shares, basic ⁽³⁾	217.9	204.1	13.8	217.9	204.1	13.8
Net loss per share, diluted ⁽²⁾	\$ (0.37)	\$ (0.33)	\$ (0.04)	\$ (0.27)	\$ (0.26)	\$ (0.01)
Weighted average shares, diluted ⁽³⁾	217.9	204.1	13.8	217.9	204.1	13.8

⁽¹⁾ Capital Expenditures reflects cash paid for property, equipment, and manufacturing assets and is a component of our free cash flow calculation. It excludes depreciation, accretion and amortization, and other non-cash investing items. It excludes one-time cash outflows related to business acquisitions. ⁽²⁾ Net loss per share attributable to Enovix. ⁽³⁾ Weighted average shares attributable to Enovix.

Financial Outlook

(unaudited, in millions, except per share data)

	Q3 2026 Guidance ⁽¹⁾	Q3 2025 Results	Q2 2026 Results
Revenue	\$9.0 - 10.0	\$8.0	\$9.0
Non-GAAP loss from operations ⁽²⁾	(\$29.0 - 32.0)	(\$29.8)	(\$28.8)
Non-GAAP net loss per share ^{(2),(3)}	(\$0.13 - 0.17)	(\$0.14)	(\$0.13)
Capital expenditures ⁽⁴⁾	\$8.0 - 12.0	\$3.0	\$9.6

⁽¹⁾ Our outlook does not include provisions for proposed tax law changes or for the recently enacted tax reform legislation, future asset impairments or for pending legal matters, other than future legal amounts that are probable and estimable. Further, due to their nature, certain income and expense items, such as certain investments, derivative and foreign currency transaction gains or losses, cannot be accurately forecast. Accordingly, we only include such items in our financial outlook to the extent they are reasonably certain. Actual results may differ materially from the outlook; ⁽²⁾ See Appendix for definitions and reconciliations of non-GAAP Gross Profit (Loss), non-GAAP Gross Margin, non-GAAP Operating Loss, Adjusted EBITDA, and non-GAAP Net Loss Per Share Attributable to Enovix to their nearest comparable GAAP metrics for the historical periods presented. We are not presenting a quantitative reconciliation of our guidance for non-GAAP Operating Loss and non-GAAP Net Loss Per Share Attributable to Enovix to their GAAP equivalents, in reliance on the unreasonable efforts exception under Item 10(e)(1)(i)(B) of Regulation S-K. Further information is provided below under the heading "Non-GAAP Financial Measures"; ⁽³⁾ non-GAAP Net Loss Per Share represents non-GAAP Net Loss Per Share Attributable to Enovix; ⁽⁴⁾ Capital Expenditures reflects cash paid for property, equipment, and manufacturing assets and is a component of our free cash flow calculation. It excludes depreciation, accretion, amortization, and other non-cash investing items. It excludes one-time cash outflows related to business acquisitions.

Conference Call Information

The Company will host a live, audio-only webcast today at **5:00 PM ET / 2:00 PM PT** to discuss the results and provide a business update. To register for the audio webcast, please visit: <https://enovix-q2-2026.open-exchange.net/>.

About Enovix

Enovix develops and manufactures advanced lithium-ion batteries, including proprietary silicon-anode architectures for smartphones, smart eyewear, defense, industrial, and emerging edge-AI applications. Its proprietary silicon-anode battery architecture enables higher energy density and performance in space-constrained devices while maintaining safety and reliability, supporting commercialization across consumer and industrial markets.

Enovix is headquartered in Silicon Valley with facilities in India, Korea, and Malaysia, serving customers globally. For more information visit <https://enovix.com> and follow us on LinkedIn.

Non-GAAP Financial Measures

This press release includes the use of non-GAAP financial measures, which are intended to provide supplemental information regarding our performance. These non-GAAP measures include non-GAAP cost of revenue, non-GAAP gross profit (loss), non-GAAP gross margin, non-GAAP research and development expense, non-GAAP selling, general and administrative expense, non-GAAP operating expenses, non-GAAP income (loss) from operations, EBITDA, adjusted EBITDA, non-GAAP net loss attributable to Enovix shareholders, non-GAAP earnings (loss) per share, free cash flow, and other non-GAAP measures that are included in this press release.

We use these non-GAAP measures to supplement our financial reporting and to evaluate ongoing operations and results, facilitate internal planning and forecasting, and assess performance against prior periods, industry peers, and the broader market. These non-GAAP measures are not prepared in accordance with generally accepted accounting principles (GAAP) and should not be considered as an alternative to GAAP results. Industry peers and other companies may calculate similar non-GAAP measures differently. Non-GAAP financial measures have limitations, including but not limited to, that they exclude certain expenses that are required under GAAP, which adjustments reflect the exercise of judgment by management. We believe that these non-GAAP measures, when considered together with the GAAP results, provide investors with an

additional understanding of our operating performance. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the tables at the end of this press release.

While Enovix provides third quarter 2026 guidance for non-GAAP loss from operations, non-GAAP net loss per share and capital expenditures, we are unable to provide without unreasonable effort a GAAP to non-GAAP reconciliation of these projected non-GAAP measures, and we have not provided a quantitative reconciliation in reliance on the unreasonable efforts exception under Item 10(e)(1)(i)(B) of Regulation S-K. Such reconciliation to the corresponding GAAP financial measure cannot be provided without unreasonable effort because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjustments that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to change in fair value of common stock, stock-based compensation and related tax effects, legal costs related to shareholder lawsuit, gain on bargain purchase of assets, acquisition-related costs, and restructuring costs. As a result, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial or operating performance and are identified by words such as anticipate, believe, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, will, would, and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding: our future operating results, financial position, growth opportunities, and guidance; expected performance, capabilities, and development of our battery products and technology roadmap; the timing, results and impact of customer testing, certification and qualification requirements; the timing and scale of sampling, product launches, production ramps, and customer programs; our ability to meet customer performance requirements and progress toward commercial deployment; our ability to scale and optimize manufacturing, including improvements in yield, throughput, dicing processes, performance, cost, timing and capital efficiency of our capacity expansion; our estimation of customer demand, adoption, growth and our ability to convert pipeline opportunities into revenue; our expectations regarding regulatory, certification and government sourcing requirements, including under the NDAA and TAA; and the sufficiency and use of our capital resources and our expectations regarding the benefits and use of our current balances of cash, cash equivalents, and marketable securities.

Risks, uncertainties and assumptions that could cause actual results to differ materially from the results and events anticipated by such forward-looking statements include, but are not limited to: risks related to the outcome of customer testing and qualification activities, including the possibility that our products do not meet required performance thresholds or that such testing is delayed beyond expected time frames; our ability to successfully develop, manufacture and commercialize our battery products and transition to high-volume production; our ability to scale manufacturing operations and achieve expected production capacity and yields; the level and timing of customer demand, qualification and adoption of our products across end markets; our ability to enter into and expand commercial agreements, including securing design wins, purchase orders and production contracts; our ability to execute on our business strategy and build and scale our sales and commercial capabilities; lengthy and unpredictable customer qualification and sales cycles, safety considerations and contractual terms, particularly in defense and other regulated markets; risks related to battery performance, reliability and safety; customer concentration in the defense sector and certain consumer technology markets, such as smartphones and smart eyewear; challenges in forecasting demand, inventory and manufacturing requirements that may result in additional costs and production delays; our history of losses and expectation of continued losses; risks associated with the development and commercialization of products that remain under development and may not be successfully produced at commercial scale; our ability to effectively integrate and derive benefits from acquired businesses; fluctuations in foreign currency exchange rates and interest rates; operational and safety risks associated with manufacturing equipment; intense competition and our ability to keep up with rapid technological change and evolving standards in the battery industry; our ability to attract and retain qualified personnel; the outcome of litigation, regulatory investigations and other legal

matters, including the associated legal and other costs; liquidity constraints, capital availability and our ability to service existing debt; our ability to protect and enforce our intellectual property rights; volatility in the trading price of our common stock; changes in tax laws or regulations; the impact of cyber and other information technology or security related incidents on us, our customers or other parties; changes in the political, economic or regulatory environment generally and in the markets in which we operate; and other risks described in the disclosures contained in our filings with the Securities and Exchange Commission (“SEC”), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our annual report on Form 10-K and quarterly reports on Form 10-Q and other documents that we have filed, or will file, with the SEC. These documents are available in the SEC Filings section of the Investor Relations page at <https://ir.enovix.com> and at www.sec.gov.

Any forward-looking statements in this press release speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Note Regarding Customer Pipeline and Design Wins

We may refer in this press release and other communications to our “customer pipeline” and “design wins.” Our customer pipeline represents our estimate of the peak annual production value of identified design opportunities for products manufactured in South Korea. A “design win” refers to an opportunity that has been awarded to Enovix but has not yet entered production. Customer pipeline and design win amounts do not represent customer orders, backlog or committed revenue and should not be viewed as forecasts of future revenue. Actual revenue, if any, will depend on a number of factors, including customer qualification, final program awards, production timing, capacity and volumes, and the successful launch and ramp of customer programs. These measures are forward-looking and are subject to the risks and uncertainties described above under “Forward-Looking Statements.”

For media and investor inquiries, please contact:

Investor Contact:

Monica Gould

ir@enovix.com

ENOVIX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except share and par value amounts)

	As of July 5, 2026	As of December 28, 2025
Assets		
Current assets:		
Cash and cash equivalents	\$ 33,741	\$ 106,014
Short-term investments	442,040	406,026
Accounts receivable, net	3,097	4,421
Notes receivable, net	—	4,012
Inventory	17,520	13,617
Prepaid expenses and other current assets	9,342	8,120
Total current assets	505,740	542,210
Property and equipment, net	165,155	170,263
Long-term investments	74,430	106,810
Customer relationship intangibles and other intangibles, net	29,168	31,638
Operating lease, right-of-use assets	8,639	11,682
Goodwill	12,217	12,217
Other assets, non-current	4,270	4,155
Total assets	\$ 799,619	\$ 878,975
Liabilities and Equity		
Current liabilities:		
Accounts payable	\$ 12,173	\$ 17,818
Accrued expenses	11,456	13,992
Accrued compensation	7,560	6,219
Short-term debt	10,593	9,865
Deferred revenue	3,710	5,015
Warrant liability	—	6,578
Other liabilities	6,618	5,529
Total current liabilities	52,110	65,016
Long-term debt, net	520,994	519,271
Operating lease liabilities, non-current	5,893	11,244
Deferred revenue, non-current	300	300
Deferred tax liability	8,320	9,119
Other liabilities, non-current	13	14
Total liabilities	587,630	604,964
Stockholders' equity:		
Common stock, \$0.0001 par value; authorized shares of 1,000,000,000; issued and outstanding shares of 219,195,932 and 216,556,238 as of July 5, 2026 and December 28, 2025, respectively	23	22
Additional paid-in-capital	1,328,872	1,307,912
Treasury stock, at cost	(58,385)	(58,385)
Accumulated other comprehensive loss	(1,415)	(508)
Accumulated deficit	(1,059,150)	(977,827)
Total Enovix's stockholders' equity	209,945	271,214
Non-controlling interest	2,044	2,797
Total equity	211,989	274,011
Total liabilities and equity	\$ 799,619	\$ 878,975

ENOVIX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, Except Share and per Share Amounts)

	Fiscal Quarters Ended		Fiscal Years-to-Date Ended	
	July 5, 2026	June 29, 2025	July 5, 2026	June 29, 2025
Revenue	\$ 9,024	\$ 7,468	\$ 16,624	\$ 12,566
Cost of revenue	7,722	5,526	13,770	10,363
Gross profit	1,302	1,942	2,854	2,203
Operating expenses:				
Research and development	24,444	28,148	50,972	54,077
Selling, general and administrative	20,154	17,527	39,073	34,419
Total operating expenses	44,598	45,675	90,045	88,496
Loss from operations	(43,296)	(43,733)	(87,191)	(86,293)
Other income (expense):				
Change in fair value of common stock warrants	181	(5,885)	6,578	9,911
Gain on bargain purchase of assets	—	4,761	—	4,761
Interest income	5,134	2,427	10,910	4,861
Interest expense	(6,521)	(1,705)	(13,529)	(3,421)
Other income (expense), net	984	(992)	1,327	1,361
Total other income (expense), net	(222)	(1,394)	5,286	17,473
Loss before income tax benefit	(43,518)	(45,127)	(81,905)	(68,820)
Income tax benefit	(441)	(861)	(570)	(1,023)
Net loss	(43,077)	(44,266)	(81,335)	(67,797)
Net gain (loss) attributable to non-controlling interest	(14)	262	(12)	241
Net loss attributable to Enovix	\$ (43,063)	\$ (44,528)	\$ (81,323)	\$ (68,038)
Net loss per share attributable to Enovix shareholders, basic and diluted ⁽¹⁾	\$ (0.20)	\$ (0.22)	\$ (0.37)	\$ (0.33)
Weighted average number of common shares outstanding, basic and diluted ⁽¹⁾	218,502,098	204,819,119	217,908,465	204,086,108

⁽¹⁾ As required by ASC 260, Earnings Per Share, the share and per share amounts presented in the above table for the fiscal quarter and fiscal year-to-date ended June 29, 2025 have been retroactively adjusted to reflect the warrant dividend issued in July 2025.

ENOVIX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)

	Fiscal Years-to-Date Ended	
	July 5, 2026	June 29, 2025
Cash flows used in operating activities:		
Net loss	\$ (81,335)	\$ (67,797)
Adjustments to reconcile net loss to net cash used in operating activities		
Depreciation, accretion and amortization	19,406	17,277
Stock-based compensation expense	24,799	26,136
Change in fair value of common stock warrants	(6,578)	(9,911)
Gain on bargain purchase of assets	—	(4,761)
Others	(1,452)	1,405
Changes in operating assets and liabilities:		
Accounts and notes receivables	5,125	(552)
Inventory	(4,249)	(5,410)
Prepaid expenses and other assets	(1,369)	1,765
Accounts payable	(3,677)	2,241
Accrued expenses and compensation	(1,660)	(5,001)
Deferred revenue	(1,328)	1,044
Deferred tax liability	(803)	(683)
Other liabilities	(1,732)	1,481
Net cash used in operating activities	(54,853)	(42,766)
Cash flows from investing activities:		
Purchase of property and equipment	(12,844)	(14,243)
Payment for business acquisition	—	(10,000)
Purchases of investments	(230,074)	(85,473)
Maturities of investments	227,580	18,627
Net cash used in investing activities	(15,338)	(91,089)
Cash flows from financing activities:		
Proceeds from loan borrowing	1,300	—
Proceeds from issuance of common stock under employee stock purchase plan	938	711
Payroll tax payments for shares withheld upon vesting of RSUs	(3,382)	(2,853)
Purchase of Routejade shares from non-controlling interest	(740)	—
Repayment of debt	(108)	(813)
Proceeds from the exercise of stock options	—	782
Payments of transaction costs related to common stock issuance	—	(512)
Net cash used in financing activities	(1,992)	(2,685)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(202)	(102)
Change in cash, cash equivalents, and restricted cash	(72,385)	(136,642)
Cash and cash equivalents and restricted cash, beginning of period	107,979	274,691
Cash and cash equivalents and restricted cash, end of period	<u>\$ 35,594</u>	<u>\$ 138,049</u>

Net Loss Attributable to Enovix to Adjusted EBITDA Reconciliation

“EBITDA” is defined as earnings (net loss) attributable to Enovix adjusted for interest income, interest expense, income tax benefit, depreciation, accretion and amortization expense. “Adjusted EBITDA” includes additional adjustments to EBITDA such as stock-based compensation expense, change in fair value of common stock warrants, impairment of equipment, warrant issuance cost, certain legal costs related to our defense of an ongoing securities class action complaint that is outside the ordinary course of business and that we do not consider representative of our performance, and other special items as determined by management which it does not believe to be indicative of its underlying business trends.

These non-GAAP measures may differ from similarly titled measures used by other companies.

Below is a reconciliation of net loss attributable to Enovix on a GAAP basis to the non-GAAP EBITDA and Adjusted EBITDA financial measures for the periods presented below (unaudited, in thousands):

	Fiscal Quarters Ended		Fiscal Years-to-Date Ended	
	July 5, 2026	June 29, 2025	July 5, 2026	June 29, 2025
Net loss attributable to Enovix	\$ (43,063)	\$ (44,528)	\$ (81,323)	\$ (68,038)
Interest expense (income), net	1,387	(722)	2,619	(1,440)
Income tax benefit	(441)	(861)	(570)	(1,023)
Depreciation, accretion and amortization	10,036	8,829	19,406	17,277
EBITDA	(32,081)	(37,282)	(59,868)	(53,224)
Stock-based compensation expense	13,034	14,122	24,799	26,136
Change in fair value of common stock warrants	(181)	5,885	(6,578)	(9,911)
Legal cost related to shareholder lawsuit ⁽¹⁾	313	1,247	2,389	2,651
Acquisition cost	—	664	—	664
Gain on bargain purchase of assets	—	(4,761)	—	(4,761)
Import duty forgiveness	—	—	—	(2,431)
Adjusted EBITDA	<u>\$ (18,915)</u>	<u>\$ (20,125)</u>	<u>\$ (39,258)</u>	<u>\$ (40,876)</u>

⁽¹⁾ These amounts reflect litigation expenses related to the defense of an ongoing securities action.

Reconciliation of Operating Loss to Non-GAAP Operating Loss and Adjusted EBITDA

Additionally, below is a reconciliation of GAAP operating loss to non-GAAP operating loss and adjusted EBITDA for the periods presented (unaudited, in thousands).

These non-GAAP measures may differ from similarly titled measures used by other companies.

	Fiscal Quarters Ended		Fiscal Years-to-Date Ended	
	July 5, 2026	June 29, 2025	July 5, 2026	June 29, 2025
GAAP loss from operations	\$ (43,296)	\$ (43,733)	\$ (87,191)	\$ (86,293)
Stock-based compensation expense	13,034	14,122	24,799	26,136
Amortization of intangible assets	1,190	1,188	2,471	2,378
Legal cost related to shareholder lawsuit ⁽¹⁾	313	1,247	2,389	2,651
Acquisition cost	—	664	—	664
Non-GAAP loss from operations	(28,759)	(26,512)	(57,532)	(54,464)
Depreciation, accretion and amortization (excluding amortization of intangible assets)	8,846	7,641	16,935	14,899
Other income (loss), net (excluding import duty forgiveness)	984	(992)	1,327	(1,070)
Net gain (loss) attributable to non-controlling interest	14	(262)	12	(241)
Adjusted EBITDA	<u>\$ (18,915)</u>	<u>\$ (20,125)</u>	<u>\$ (39,258)</u>	<u>\$ (40,876)</u>

⁽¹⁾ These amounts reflect litigation expenses related to the defense of an ongoing securities action.

Free Cash Flow Reconciliation

We define “Free Cash Flow” as (i) net cash from operating activities less (ii) capital expenditures, net of proceeds from disposals of property and equipment, all of which are derived from our Consolidated Statements of Cash Flow. The presentation of non-GAAP Free Cash Flow is not intended as an alternative measure of cash flows from operations, as determined in accordance with GAAP.

We believe Free Cash Flow is a useful measure for investors because it provides insight into the cash generated or used by our operations after funding capital expenditures, and it helps assess our ability to pursue strategic growth initiatives. We use Free Cash Flow internally to evaluate performance, support decision-making, and measure our progress toward profitability and cash flow breakeven.

This non-GAAP measure may differ from similarly titled measures used by other companies.

Below is a reconciliation of net cash used in operating activities to the Free Cash Flow financial measures for the periods presented below (unaudited, in thousands):

	Fiscal Years-to-Date Ended	
	July 5, 2026	June 29, 2025
Net cash used in operating activities	\$ (54,853)	\$ (42,766)
Capital expenditures	(12,844)	(14,243)
Free cash flow	\$ (67,697)	\$ (57,009)

Other Non-GAAP Financial Measures Reconciliation

(Unaudited, in thousands, except share and per share amounts)

These non-GAAP measures may differ from similarly titled measures used by other companies.

	Fiscal Quarters Ended		Fiscal Years-to-Date Ended	
	July 5, 2026	June 29, 2025	July 5, 2026	June 29, 2025
Revenue	\$ 9,024	\$ 7,468	\$ 16,624	\$ 12,566
Cost of revenue:				
GAAP cost of revenue	\$ 7,722	\$ 5,526	\$ 13,770	\$ 10,363
Stock-based compensation expense	(490)	(356)	(935)	(477)
Non-GAAP cost of revenue	<u>\$ 7,232</u>	<u>\$ 5,170</u>	<u>\$ 12,835</u>	<u>\$ 9,886</u>
GAAP gross profit	\$ 1,302	\$ 1,942	\$ 2,854	\$ 2,203
Stock-based compensation expense	490	356	935	477
Non-GAAP gross profit	<u>\$ 1,792</u>	<u>\$ 2,298</u>	<u>\$ 3,789</u>	<u>\$ 2,680</u>
GAAP research and development (R&D) expense	\$ 24,444	\$ 28,148	\$ 50,972	\$ 54,077
Stock-based compensation expense	(4,620)	(6,941)	(9,690)	(13,296)
Amortization of intangible assets	(416)	(415)	(864)	(831)
Non-GAAP R&D expense	<u>\$ 19,408</u>	<u>\$ 20,792</u>	<u>\$ 40,418</u>	<u>\$ 39,950</u>
GAAP selling, general and administrative (SG&A) expense	\$ 20,154	\$ 17,527	\$ 39,073	\$ 34,419
Stock-based compensation expense	(7,924)	(6,825)	(14,174)	(12,363)
Amortization of intangible assets	(774)	(773)	(1,607)	(1,547)
Legal cost related to shareholder lawsuit ⁽¹⁾	(313)	(1,247)	(2,389)	(2,651)
Acquisition cost	—	(664)	—	(664)
Non-GAAP SG&A expense	<u>\$ 11,143</u>	<u>\$ 8,018</u>	<u>\$ 20,903</u>	<u>\$ 17,194</u>
GAAP operating expenses	\$ 44,598	\$ 45,675	\$ 90,045	\$ 88,496
Stock-based compensation expense included in R&D expense	(4,620)	(6,941)	(9,690)	(13,296)
Stock-based compensation expense included in SG&A expense	(7,924)	(6,825)	(14,174)	(12,363)
Amortization of intangible assets	(1,190)	(1,188)	(2,471)	(2,378)
Legal cost related to shareholder lawsuit ⁽¹⁾	(313)	(1,247)	(2,389)	(2,651)
Acquisition cost	—	(664)	—	(664)
Non-GAAP operating expenses	<u>\$ 30,551</u>	<u>\$ 28,810</u>	<u>\$ 61,321</u>	<u>\$ 57,144</u>

⁽¹⁾ These amounts reflect litigation expenses related to the defense of an ongoing securities action.

	Fiscal Quarters Ended		Fiscal Years-to-Date Ended	
	July 5, 2026	June 29, 2025	July 5, 2026	June 29, 2025
GAAP loss from operations	\$ (43,296)	\$ (43,733)	\$ (87,191)	\$ (86,293)
Stock-based compensation expense	13,034	14,122	24,799	26,136
Amortization of intangible assets	1,190	1,188	2,471	2,378
Legal cost related to shareholder lawsuit ⁽¹⁾	313	1,247	2,389	2,651
Acquisition cost	—	664	—	664
Non-GAAP loss from operations	<u>\$ (28,759)</u>	<u>\$ (26,512)</u>	<u>\$ (57,532)</u>	<u>\$ (54,464)</u>
GAAP net loss attributable to Enovix	\$ (43,063)	\$ (44,528)	\$ (81,323)	\$ (68,038)
Stock-based compensation expense	13,034	14,122	24,799	26,136
Change in fair value of common stock warrants	(181)	5,885	(6,578)	(9,911)
Amortization of intangible assets	1,190	1,188	2,471	2,378
Legal cost related to shareholder lawsuit ⁽¹⁾	313	1,247	2,389	2,651
Acquisition cost	—	664	—	664
Gain on bargain purchase of assets	—	(4,761)	—	(4,761)
Import duty forgiveness	—	—	—	(2,431)
Non-GAAP net loss attributable to Enovix shareholders	<u>\$ (28,707)</u>	<u>\$ (26,183)</u>	<u>\$ (58,242)</u>	<u>\$ (53,312)</u>
GAAP net loss per share attributable to Enovix, basic and diluted⁽²⁾	\$ (0.20)	\$ (0.22)	\$ (0.37)	\$ (0.33)
GAAP weighted average number of common shares outstanding, basic and diluted ⁽²⁾	218,502,098	204,819,119	217,908,465	204,086,108
Non-GAAP net loss per share attributable to Enovix, basic and diluted⁽²⁾	\$ (0.13)	\$ (0.13)	\$ (0.27)	\$ (0.26)
GAAP weighted average number of common shares outstanding, basic and diluted ⁽²⁾	218,502,098	204,819,119	217,908,465	204,086,108

⁽¹⁾ These amounts reflect litigation expenses related to the defense of an ongoing securities action.

⁽²⁾ As required by ASC 260, Earnings Per Share, the share and per share amounts presented in the above table for the fiscal quarter and fiscal year-to-date ended June 29, 2025 have been retroactively adjusted to reflect the warrant dividend issued in July 2025.